Israel Englander Verve Therapeutics, Inc. Call Options Transaction History

Millennium Management LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$4.4 - $7.86 $171,600 - $306,540	-39,000 Reduced 39.0%	61,000 $295,000
Q2 2024 Aug 14, 2024	BUY	$4.76 - $12.79 $476,000 - $1.28 Million	100,000 New	100,000 $488,000
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $1.1 Million - $2.92 Million	70,400 New	70,400 $2.42 Million

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $318M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.